ETOXIB FILM-COATED TABLETS 30MG

Krka, d.d., Novo mesto (SLOVENIA)Unichem Laboratories Limited (INDIA)Krka, tovarna zdravil, d.d. (SLOVENIA)🇸🇬 Health Sciences Authority

Approval Date: Mar 19, 2021
Approval ID: 219f2b0cbf18fb62
Company: Krka, d.d., Novo mesto (SLOVENIA)Unichem Laboratories Limited (INDIA)Krka, tovarna zdravil, d.d. (SLOVENIA)
Type: Therapeutic

Approval Details

Approval Id: 219f2b0cbf18fb62
Drug Name: ETOXIB FILM-COATED TABLETS 30MG
Product Name: ETOXIB FILM-COATED TABLETS 30MG
Approval Number: SIN16126P
Approval Date: 2021-03-19
Registrant: SINGAPORE PHARMACEUTICAL PRIVATE LIMITED
Licence Holder: SINGAPORE PHARMACEUTICAL PRIVATE LIMITED
Drug Type: Therapeutic
Forensic Classification: Prescription Only
Dosage Form: TABLET, FILM COATED
Dosage: 4.2 Posology and method of administration Posology As the cardiovascular risks of etoricoxib may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. The patient’s need for symptomatic relief and response to therapy should be re-evaluated periodically, especially in patients with osteoarthritis (see sections 4.3, 4.4, 4.8 and 5.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Osteoarthritis The recommended dose is 30 mg once daily. In some patients with insufficient relief from symptoms, an increased dose of 60 mg once daily may increase efficacy. In the absence of an increase in therapeutic benefit, other therapeutic options should be considered. Rheumatoid arthritis The recommended dose is 60 mg once daily. In some patients with insufficient relief from symptoms, an increased dose of 90 mg once daily may increase efficacy. Once the patient has clinically stabilized, a dose reduction to 60 mg once daily may be appropriate. In the absence of an increase in therapeutic benefit, other therapeutic options should be considered. Ankylosing spondylitis The recommended dose is 60 mg once daily. In some patients with insufficient relief from symptoms, an increased dose of 90 mg once daily may increase efficacy. Once the patient has clinically stabilized, a dose reduction to 60 mg once daily may be appropriate. In the absence of an increase in therapeutic benefit, other therapeutic options should be considered. Treatment of acute pain For acute pain conditions, the recommended dose is 90 mg or 120 mg once daily. Etoricoxib should be used only for the acute symptomatic period, limited to a maximum of 8 days treatment. Acute gouty arthritis The recommended dose is 120 mg once daily. Etoricoxib 120 mg should be used only for the acute symptomatic period, limited to a maximum of 8 days treatment. In clinical trials for acute gouty arthritis, etoricoxib was given for 8 days. Primary Dysmenorrhea The recommended dose is 120 mg once daily. Post-Procedure Dental Pain The recommended dose is 90 mg once daily, limited to a maximum of 3 days. Some patients may require other postoperative analgesia in addition to Etoxib during the three day treatment period. Doses greater than those recommended for each indication have either not demonstrated additional efficacy or have not been studied. Therefore: The dose for OA should not exceed 60 mg daily. The dose for RA should not exceed 90 mg daily. The dose for ankylosing spondylitis should not exceed 90 mg daily. The dose for acute gout should not exceed 120 mg daily. The dose for acute pain and primary dysmenorrhea should not exceed 120 mg daily. The dose for post-procedure dental surgery pain should not exceed 90 mg daily. Special populations Elderly patients No dosage adjustment is necessary for elderly patients. As with other drugs, caution should be exercised in elderly patients (see section 4.4 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Patients with hepatic impairment Regardless of indication, in patients with mild hepatic dysfunction (Child-Pugh score 5–6) a dose of 60 mg once daily should not be exceeded. In patients with moderate hepatic dysfunction (Child-Pugh score 7–9), regardless of indication, the dose of 60 mg every other day should not be exceeded; administration of 30 mg once daily can also be considered. Clinical experience is limited particularly in patients with moderate hepatic dysfunction and caution is advised. There is no clinical experience in patients with severe hepatic dysfunction (Child-Pugh score ≥10); therefore, its use is contra-indicated in these patients (see sections 4.3, 4.4 and 5.2 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Patients with renal impairment No dosage adjustment is necessary for patients with creatinine clearance ≥30 ml/min (see section 5.2 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). The use of etoricoxib in patients with creatinine clearance <30 ml/min is contra-indicated (see sections 4.3 and 4.4 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Paediatric population Etoricoxib is contra-indicated in children and adolescents under 16 years of age (see section 4.3). Method of administration Etoxib is administered orally and may be taken with or without food. The onset of the effect of the medicinal product may be faster when Etoxib is administered without food. This should be considered when rapid symptomatic relief is needed.
Route Of Administration: ORAL
Indication Info: 4.1 Therapeutic indications Etoxib is indicated in adults and adolescents 16 years of age and older for the symptomatic relief of osteoarthritis (OA), rheumatoid arthritis (RA), symptomatic relief of ankylosing spondylitis (AS), and the pain and signs of inflammation associated with acute gouty arthritis. Etoxib is indicated in adults and adolescents 16 years of age and older for the treatment of acute pain, including that related to primary dysmenorrhea and minor dental procedures. The decision to prescribe a selective COX-2 inhibitor should be based on an assessment of the individual patient’s overall risks, taking into consideration other available therapeutic options (see sections 4.3, 4.4 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Contraindications: 4.3 Contraindications <ul class="dash"> <li>Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.</li> <li>Active peptic ulceration or active gastro-intestinal (GI) bleeding.</li> <li>Patients who, after taking acetylsalicylic or NSAIDs including COX-2 (cyclooxygenase-2) inhibitors, experience asthma, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria, or allergic-type reactions.</li> <li>Pregnancy and lactation (see sections 4.6 and 5.3 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).</li> <li>Severe hepatic dysfunction (serum albumin <25 g/l or Child-Pugh score ≥10).</li> <li>Estimated renal creatinine clearance <30 ml/min.</li> <li>Children and adolescents under 16 years of age.</li> <li>Inflammatory bowel disease.</li> <li>Congestive heart failure (NYHA II–IV).</li> <li>Patients with hypertension whose blood pressure is persistently elevated above 140/90mmHg and has not been adequately controlled.</li> <li>Patients with established ischemic heart disease, peripheral arterial disease and/or cerebrovascular disease (including patients who have recently undergone coronary artery bypass graft surgery or angioplasty).</li> </ul>
Atc Code: M01AH05
Atc Item Name: etoricoxib
Pharma Manufacturer Name: SINGAPORE PHARMACEUTICAL PRIVATE LIMITED

Active Ingredients

Etoricoxib

30.00mg

ETORICOXIB

30 MG

Approved

Quick Info

Agency

HSA

Country

🇸🇬

Approval Date

Mar 19, 2021

Approval ID

219f2b0cbf18fb62

Type

Therapeutic

Back to HSA Approvals